Cargando…

Ferric Carboxymatose in Non-Hemodialysis CKD Patients: A Longitudinal Cohort Study

No information is available on the efficacy of ferric carboxymaltose (FCM) in real-world CKD patients outside the hemodialysis setting. We prospectively followed 59 non-hemodialysis CKD patients with iron deficient anemia (IDA: hemoglobin <12.0/<13.5 g/dL in women/men and TSAT < 20% and/or...

Descripción completa

Detalles Bibliográficos
Autores principales:	Minutolo, Roberto, Berto, Patrizia, Liberti, Maria Elena, Peruzzu, Nicola, Borrelli, Silvio, Netti, Antonella, Garofalo, Carlo, Conte, Giuseppe, De Nicola, Luca, Del Vecchio, Lucia, Locatelli, Francesco
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8005153/ https://www.ncbi.nlm.nih.gov/pubmed/33806864 http://dx.doi.org/10.3390/jcm10061322

Ejemplares similares

New-onset anemia and associated risk of ESKD and death in non-dialysis CKD patients: a multicohort observational study
por: Minutolo, Roberto, et al.
Publicado: (2022)

Current Management of Hyperkalemia in Non-Dialysis CKD: Longitudinal Study of Patients Receiving Stable Nephrology Care
por: Borrelli, Silvio, et al.
Publicado: (2021)

Epidemiology of CKD Regression in Patients under Nephrology Care
por: Borrelli, Silvio, et al.
Publicado: (2015)

SGLT2 Inhibitors: Nephroprotective Efficacy and Side Effects
por: Garofalo, Carlo, et al.
Publicado: (2019)

Sustained Recovery of Kidney Function in Patients with ESKD under Chronic Dialysis Treatment: Systematic Review and Meta-Analysis
por: Garofalo, Carlo, et al.
Publicado: (2023)

Prognosis and determinants of serum PTH changes over time in 1-5 CKD stage patients followed in tertiary care
por: Borrelli, Silvio, et al.
Publicado: (2018)

Independent Role of Underlying Kidney Disease on Renal Prognosis of Patients with Chronic Kidney Disease under Nephrology Care
por: De Nicola, Luca, et al.
Publicado: (2015)

Efficacy, Safety and Pharmacoeconomic Analysis of Intravenous Ferric Carboxymaltose in Anemic Hemodialysis Patients Unresponsive to Ferric Gluconate Treatment: A Multicenter Retrospective Study
por: Rosati, Alberto, et al.
Publicado: (2022)

Dietary Salt Restriction in Chronic Kidney Disease: A Meta-Analysis of Randomized Clinical Trials
por: Garofalo, Carlo, et al.
Publicado: (2018)

The effect of a ketogenic diet on weight loss in CKD: a randomized controlled trial in obese stage G1–3a CKD patients
por: Zoccali, Carmine, et al.
Publicado: (2023)

Resistant Hypertension in Nondialysis Chronic Kidney Disease
por: Borrelli, Silvio, et al.
Publicado: (2013)

Thiazide diuretics are back in CKD: the case of chlorthalidone
por: Minutolo, Roberto, et al.
Publicado: (2022)

Sodium Intake and Chronic Kidney Disease
por: Borrelli, Silvio, et al.
Publicado: (2020)

Antiproteinuric effect of add-on paricalcitol in CKD patients under maximal tolerated inhibition of renin-angiotensin system: a prospective observational study
por: De Nicola, Luca, et al.
Publicado: (2012)

Nephroprotection by SGLT2 Inhibition: Back to the Future?
por: De Nicola, Luca, et al.
Publicado: (2020)

Safety of intravenous ferric carboxymaltose versus oral iron in patients with nondialysis-dependent CKD: an analysis of the 1-year FIND-CKD trial
por: Roger, Simon D., et al.
Publicado: (2017)

Evolving Strategies in the Treatment of Anaemia in Chronic Kidney Disease: The HIF-Prolyl Hydroxylase Inhibitors
por: Locatelli, Francesco, et al.
Publicado: (2022)

Volume-Independent Sodium Toxicity in Peritoneal Dialysis: New Insights from Bench to Bed
por: Borrelli, Silvio, et al.
Publicado: (2021)

Role of Albuminuria in Detecting Cardio-Renal Risk and Outcome in Diabetic Subjects
por: Pafundi, Pia Clara, et al.
Publicado: (2021)

Competing-Risk Analysis of Death and End Stage Kidney Disease by Hyperkalaemia Status in Non-Dialysis Chronic Kidney Disease Patients Receiving Stable Nephrology Care
por: Provenzano, Michele, et al.
Publicado: (2018)

Ferric carboxymaltose versus ferric gluconate in hemodialysis patients: reduction of erythropoietin dose in 4 years of follow-up
por: Lacquaniti, Antonio, et al.
Publicado: (2020)

Epidemiology of low-proteinuric chronic kidney disease in renal clinics
por: De Nicola, Luca, et al.
Publicado: (2017)

The Switch from Ferric Gluconate to Ferric Carboxymaltose in Hemodialysis Patients Acts on Iron Metabolism, Erythropoietin, and Costs: A Retrospective Analysis
por: Lacquaniti, Antonio, et al.
Publicado: (2023)

Evaluation of iron stores in hemodialysis patients on maintenance ferric Carboxymaltose dosing
por: Diebold, Matthias, et al.
Publicado: (2019)

Nutritional treatment of advanced CKD: twenty consensus statements
por: Cupisti, Adamasco, et al.
Publicado: (2018)

Segregating the effects of ferric citrate‐mediated iron utilization and FGF23 in a mouse model of CKD
por: Liesen, Michael P., et al.
Publicado: (2022)

The anaemia treatment journey of CKD patients: from epoetins to hypoxia-inducible factor-prolyl hydroxylase inhibitors
por: Locatelli, Francesco, et al.
Publicado: (2023)

Switching iron sucrose to ferric carboxymaltose associates to better control of iron status in hemodialysis patients
por: Hofman, Jesse M. G., et al.
Publicado: (2018)

Renal function in patients with non-dialysis chronic kidney disease receiving intravenous ferric carboxymaltose: an analysis of the randomized FIND-CKD trial
por: Macdougall, Iain C., et al.
Publicado: (2017)

FIND-CKD: a randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia
por: Macdougall, Iain C., et al.
Publicado: (2014)

Economic Evaluation of Ferric Carboxymaltose for the Management of Hemodialysis Patients with Iron Deficiency Anemia in Italy
por: Rognoni, Carla, et al.
Publicado: (2019)

High mortality of CKD patients on hemodialysis with Covid-19 in Brazil
por: Pio-Abreu, Andrea, et al.
Publicado: (2020)

NaPi-IIb Inhibition for Hyperphosphatemia in CKD Hemodialysis Patients
por: Maruyama, Sonomi, et al.
Publicado: (2020)

Pharmacokinetics of ferric pyrophosphate citrate administered via dialysate and intravenously to pediatric patients on chronic hemodialysis
por: Pratt, Raymond D., et al.
Publicado: (2018)

Editorial: Management of Patients With Non-dialysis Dependent Chronic Kidney Disease (ND-CKD)
por: Provenzano, Michele, et al.
Publicado: (2022)

Super and ferric: the first HL-LHC component is ready
por: Antonella Del Rosso
Publicado: (2016)

Physiologically based pharmacokinetic-pharmacodynamic evaluation of meropenem in CKD and hemodialysis individuals
por: Deng, Guoliang, et al.
Publicado: (2023)

Longitudinal Bone Loss Occurs at the Radius in CKD
por: Cailleaux, Pierre-Emmanuel, et al.
Publicado: (2021)

Serum Erythroferrone Levels Associate with Mortality and Cardiovascular Events in Hemodialysis and in CKD Patients: A Two Cohorts Study
por: Spoto, Belinda, et al.
Publicado: (2019)

Response rates to HB vaccine in CKD stages 3-4 and hemodialysis patients
por: Ghadiani, Mohammad H., et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_jr8o63312un1pkcblelbm31u95